Immunomodulation: Immunoglobulin Preparations Suppress Hyperinflammation in a COVID-19 Model via FcγRIIA and FcαRI
暂无分享,去创建一个
[1] A. Casadevall,et al. Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma , 2021, mBio.
[2] L. Valsecchi,et al. IL-1 Receptor Antagonist Anakinra in the Treatment of COVID-19 Acute Respiratory Distress Syndrome: A Retrospective, Observational Study , 2021, The Journal of Immunology.
[3] H. Ljunggren,et al. High-dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of granulocytes in COVID-19 , 2021, Proceedings of the National Academy of Sciences.
[4] B. G. Rao,et al. Calming the Storm: Natural Immunosuppressants as Adjuvants to Target the Cytokine Storm in COVID-19 , 2021, Frontiers in Pharmacology.
[5] R. Balk,et al. COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions , 2021, mBio.
[6] M. Fartoukh,et al. Bacterial coinfection in critically ill COVID-19 patients with severe pneumonia , 2021, Infection.
[7] M. van Egmond,et al. IgA and FcαRI: Versatile Players in Homeostasis, Infection, and Autoimmunity , 2021, ImmunoTargets and therapy.
[8] Hassan Mahmoudi. Bacterial co-infections and antibiotic resistance in patients with COVID-19 , 2020, GMS hygiene and infection control.
[9] J. Mestecky,et al. Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 Infection , 2020, Frontiers in Immunology.
[10] You-Wen He,et al. A Potential Role of Interleukin 10 in COVID-19 Pathogenesis , 2020, Trends in Immunology.
[11] S. Ciesek,et al. Analysis of Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection , 2020, The Journal of Infectious Diseases.
[12] A. Andiappan,et al. Whole blood immunophenotyping uncovers immature neutrophil-to-VD2 T-cell ratio as an early marker for severe COVID-19 , 2020, Nature Communications.
[13] Yang Wang,et al. Serological analysis reveals an imbalanced IgG subclass composition associated with COVID-19 disease severity , 2020, Cell Reports Medicine.
[14] Salleh N. Ehaideb,et al. Evidence of a wide gap between COVID-19 in humans and animal models: a systematic review , 2020, Critical Care.
[15] G. Gorochov,et al. When Therapeutic IgA Antibodies Might Come of Age. , 2020, Pharmacology.
[16] K. Stiasny,et al. Kinetics of SARS-CoV-2 specific antibodies (IgM, IgA, IgG) in non-hospitalized patients four months following infection , 2020, Journal of Infection.
[17] M. Farcet,et al. No SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected Before the 2020 Pandemic , 2020, The Journal of infectious diseases.
[18] Robert A. Campbell,et al. Cytokine release syndrome in COVID-19: Innate immune, vascular, and platelet pathogenic factors differ in severity of disease and sex , 2020, Journal of leukocyte biology.
[19] Xueying Zheng,et al. Decline of SARS-CoV-2-specific IgG, IgM and IgA in convalescent COVID-19 patients within 100 days after hospital discharge , 2020, Science China Life Sciences.
[20] S. Pancani,et al. Closing the serological gap in the diagnostic testing for COVID‐19: The value of anti‐SARS‐CoV‐2 IgA antibodies , 2020, Journal of medical virology.
[21] P. Jorth,et al. The Unrecognized Threat of Secondary Bacterial Infections with COVID-19 , 2020, mBio.
[22] G. Natoli,et al. Persistence of Anti-SARS-CoV-2 Antibodies in Non-Hospitalized COVID-19 Convalescent Health Care Workers , 2020, medRxiv.
[23] Kira L. Newman,et al. Distinct Early Serological Signatures Track with SARS-CoV-2 Survival , 2020, Immunity.
[24] N. Zhong,et al. Characteristics and roles of severe acute respiratory syndrome coronavirus 2‐specific antibodies in patients with different severities of coronavirus 19 , 2020, Clinical and experimental immunology.
[25] N. Maturo,et al. Administration of Immunoglobulins in SARS-CoV-2-Positive Patient Is Associated With Fast Clinical and Radiological Healing: Case Report , 2020, Frontiers in Medicine.
[26] Aaron M. Rosenfeld,et al. Comprehensive mapping of immune perturbations associated with severe COVID-19 , 2020, Science Immunology.
[27] W. Cao,et al. High-Dose Intravenous Immunoglobulins in the Treatment of Severe Acute Viral Pneumonia: The Known Mechanisms and Clinical Effects , 2020, Frontiers in Immunology.
[28] R. Sanders,et al. Anti-SARS-CoV-2 IgG from severely ill COVID-19 patients promotes macrophage hyper-inflammatory responses , 2020, bioRxiv.
[29] V. Martel-Laferrière,et al. Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals , 2020, mBio.
[30] A. Didangelos. COVID-19 Hyperinflammation: What about Neutrophils? , 2020, mSphere.
[31] H. Xiong,et al. Immune‐related factors associated with pneumonia in 127 children with coronavirus disease 2019 in Wuhan , 2020, Pediatric pulmonology.
[32] Jian-yong Li,et al. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids , 2020, Frontiers in Immunology.
[33] O. Schwartz,et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2 , 2020, Science Translational Medicine.
[34] H. Anders,et al. Neutrophils and Neutrophil Extracellular Traps Drive Necroinflammation in COVID-19 , 2020, Cells.
[35] J. Pačes,et al. COVID-19 and the immune system. , 2020, Physiological research.
[36] Yajuan Li,et al. Serum IgA, IgM, and IgG responses in COVID-19 , 2020, Cellular & Molecular Immunology.
[37] D. Hoffmann,et al. Excessive Neutrophils and Neutrophil Extracellular Traps in COVID-19 , 2020, Frontiers in Immunology.
[38] Paweł P. Łabaj,et al. Altered cytokine levels and immune responses in patients with SARS-CoV-2 infection and related conditions , 2020, Cytokine.
[39] M. Lanza,et al. Successful intravenous immunoglobulin treatment in severe COVID-19 pneumonia , 2020, IDCases.
[40] H. Hakonarson,et al. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients , 2020, European Respiratory Journal.
[41] B. Zhu,et al. Co-infection with respiratory pathogens among COVID-2019 cases , 2020, Virus Research.
[42] Douglas R. McDonald,et al. Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!☆ , 2020, Clinical Immunology.
[43] M. Merad,et al. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages , 2020, Nature Reviews Immunology.
[44] R. Dudley,et al. Immunomodulation in COVID-19 , 2020, The Lancet Respiratory Medicine.
[45] G. Di Gennaro,et al. Editorial - High dose intravenous immunoglobulins as a therapeutic option for COVID-19 patients. , 2020, European review for medical and pharmacological sciences.
[46] P. Matricardi,et al. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study , 2020, Clinica Chimica Acta.
[47] Leiliang Zhang,et al. A potential inhibitory role for integrin in the receptor targeting of SARS-CoV-2 , 2020, Journal of Infection.
[48] D. McGonagle,et al. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease , 2020, Autoimmunity Reviews.
[49] A. Singanayagam,et al. Immunosuppression for hyperinflammation in COVID-19: a double-edged sword? , 2020, The Lancet.
[50] Ying Wang,et al. COVID-19 infection: the perspectives on immune responses , 2020, Cell Death & Differentiation.
[51] Qi Jin,et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[52] Mandeep R. Mehra,et al. COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal , 2020, The Journal of Heart and Lung Transplantation.
[53] A. Walls,et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.
[54] Chunlin Cai,et al. Short-term Moderate-dose Corticosteroid Plus Immunoglobulin Effectively Reverses Covid-19 Patients Who Have Failed Low-dose Therapy , 2020 .
[55] Yuntao Wu,et al. Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools , 2020, Virologica Sinica.
[56] P. Mehta,et al. COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.
[57] T. Bai,et al. High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019 , 2020, Open forum infectious diseases.
[58] F. Lu,et al. Correlation Analysis Between Disease Severity and Inflammation-related Parameters in Patients with COVID-19 Pneumonia , 2020, medRxiv.
[59] Zunyou Wu,et al. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.
[60] Shuye Zhang,et al. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses , 2020, bioRxiv.
[61] Suxin Wan,et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP) , 2020, medRxiv.
[62] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[63] W. Cao,et al. Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia , 2020, Emerging microbes & infections.
[64] R. Liu,et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors , 2020, Emerging microbes & infections.
[65] F. Jönsson,et al. Expression, Role, and Regulation of Neutrophil Fcγ Receptors , 2019, Front. Immunol..
[66] L. Koenderman. Corrigendum: Inside-Out Control of Fc-Receptors , 2019, Front. Immunol..
[67] Andreas Radbruch,et al. Functional Roles of the IgM Fc Receptor in the Immune System , 2019, Front. Immunol..
[68] M. Benhamou,et al. Understanding Fc Receptor Involvement in Inflammatory Diseases: From Mechanisms to New Therapeutic Tools , 2019, Front. Immunol..
[69] J. Jansen,et al. Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG , 2019, Front. Immunol..
[70] Chuan Qin,et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. , 2019, JCI insight.
[71] T. K. van den Berg,et al. FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils , 2019, Front. Immunol..
[72] M. Romans. Altered , 2019 .
[73] Lin Qiu,et al. Understanding the Multifaceted Role of Neutrophils in Cancer and Autoimmune Diseases , 2018, Front. Immunol..
[74] D. Velissaris,et al. The use of IgM‐enriched immunoglobulin in adult patients with sepsis , 2018, Journal of critical care.
[75] Robert M. DiFazio,et al. Advanced model systems and tools for basic and translational human immunology , 2018, Genome Medicine.
[76] M. D. de Jonge,et al. Limited Innovations After More Than 65 Years of Immunoglobulin Replacement Therapy: Potential of IgA- and IgM-Enriched Formulations to Prevent Bacterial Respiratory Tract Infections , 2018, Front. Immunol..
[77] M. Singer,et al. Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study) , 2018, Intensive Care Medicine.
[78] J. Cervera,et al. Imiquimod inhibits growth and induces differentiation of myeloid leukemia cell lines , 2018, Cancer Cell International.
[79] S. Kaveri,et al. IVIG-mediated effector functions in autoimmune and inflammatory diseases , 2017, International immunology.
[80] S. Collins,et al. A map of gene expression in neutrophil-like cell lines , 2017, bioRxiv.
[81] J. Benschop,et al. Peptide mimetics of immunoglobulin A (IgA) and FcαRI block IgA‐induced human neutrophil activation and migration , 2017, European journal of immunology.
[82] E. Daugas,et al. Lyn and Fyn function as molecular switches that control immunoreceptors to direct homeostasis or inflammation , 2017, Nature Communications.
[83] P. Späth,et al. Clinical Use and Therapeutic Potential of IVIG/SCIG, Plasma-Derived IgA or IgM, and Other Alternative Immunoglobulin Preparations , 2017, Archivum Immunologiae et Therapiae Experimentalis.
[84] Colleen B. Jonsson,et al. A Role for Neutrophils in Viral Respiratory Disease , 2017, Front. Immunol..
[85] V. Martín,et al. IL-10: A Multifunctional Cytokine in Viral Infections , 2017, Journal of immunology research.
[86] H. Naim,et al. Antimicrobial activity of HL-60 cells compared to primary blood-derived neutrophils against Staphylococcus aureus , 2017, Journal of Negative Results in BioMedicine.
[87] Marieke H. Heineke,et al. Immunoglobulin A: magic bullet or Trojan horse? , 2017, European journal of clinical investigation.
[88] M. Andersen,et al. Elimination of erroneous results in flow cytometry caused by antibody binding to Fc receptors on human monocytes and macrophages , 2016, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[89] S. Stehr,et al. IgM‐enriched solution BT086 improves host defense capacity and energy store preservation in a rabbit model of endotoxemia , 2015, Acta anaesthesiologica Scandinavica.
[90] A. Zuercher,et al. Reversal of Arthritis by Human Monomeric IgA Through the Receptor‐Mediated SH2 Domain–Containing Phosphatase 1 Inhibitory Pathway , 2015, Arthritis & rheumatology.
[91] D. Baeten,et al. Control of Cytokine Production by Human Fc Gamma Receptors: Implications for Pathogen Defense and Autoimmunity , 2015, Front. Immunol..
[92] J. Seoh,et al. Phenotypic and Functional Analysis of HL-60 Cells Used in Opsonophagocytic-Killing Assay for Streptococcus pneumoniae , 2015, Journal of Korean medical science.
[93] J. V. van Strijp,et al. Neutrophil-Mediated Phagocytosis of Staphylococcus aureus , 2014, Front. Immunol..
[94] P. Bruhns,et al. Shifting FcγRIIA-ITAM from activation to inhibitory configuration ameliorates arthritis. , 2014, The Journal of clinical investigation.
[95] V. Everts,et al. IgA Enhances NETosis and Release of Neutrophil Extracellular Traps by Polymorphonuclear Cells via Fcα Receptor I , 2014, The Journal of Immunology.
[96] M. van Egmond,et al. Neutrophils as effector cells for antibody-based immunotherapy of cancer. , 2013, Seminars in cancer biology.
[97] P. Kubes,et al. Neutrophil recruitment and function in health and inflammation , 2013, Nature Reviews Immunology.
[98] F. Nimmerjahn,et al. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? , 2013, Nature Reviews Immunology.
[99] E. Gelfand. Intravenous immune globulin in autoimmune and inflammatory diseases. , 2012, The New England journal of medicine.
[100] B. Crestani,et al. IgG1 and IVIg induce inhibitory ITAM signaling through FcγRIII controlling inflammatory responses. , 2012, Blood.
[101] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[102] J. Bakema,et al. The human immunoglobulin A Fc receptor FcαRI: a multifaceted regulator of mucosal immunity , 2011, Mucosal Immunology.
[103] J. Peiris,et al. Anti-Severe Acute Respiratory Syndrome Coronavirus Spike Antibodies Trigger Infection of Human Immune Cells via a pH- and Cysteine Protease-Independent FcγR Pathway , 2011, Journal of Virology.
[104] M. Schilham,et al. Targeting FcαRI on Polymorphonuclear Cells Induces Tumor Cell Killing through Autophagy , 2011, The Journal of Immunology.
[105] M. van Egmond,et al. Immunoglobulin A , 2011, mAbs.
[106] D. Irvine,et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. , 2010, Journal of immunological methods.
[107] M. Benhamou,et al. Inhibitory ITAMs as novel regulators of immunity , 2009, Immunological reviews.
[108] Jae Hoon Kim,et al. NSC-87877, inhibitor of SHP-1/2 PTPs, inhibits dual-specificity phosphatase 26 (DUSP26). , 2009, Biochemical and biophysical research communications.
[109] G. Vidarsson,et al. Inside-Out Regulation of FcαRI (CD89) Depends on PP2A1 , 2008, The Journal of Immunology.
[110] R. Fleck,et al. Use of HL-60 Cell Line To Measure Opsonic Capacity of Pneumococcal Antibodies , 2005, Clinical Diagnostic Laboratory Immunology.
[111] C. Hughes,et al. Of Mice and Not Men: Differences between Mouse and Human Immunology , 2004, The Journal of Immunology.
[112] T. Hudson,et al. GeneExpression in HL60 Granulocytoids and Human PolymorphonuclearLeukocytes Exposed to Candidaalbicans† , 2004, Infection and Immunity.
[113] Clinton L White,et al. Bivalent binding of IgA1 to FcalphaRI suggests a mechanism for cytokine activation of IgA phagocytosis. , 2003, Journal of molecular biology.
[114] S. Jolles. High‐dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders , 2002, Clinical and experimental immunology.
[115] T. van der Poll,et al. Proinflammatory Effects of IL-10 During Human Endotoxemia1 , 2000, The Journal of Immunology.
[116] G. Mufti,et al. Changes in antigen expression on differentiating HL60 cells treated with dimethylsulphoxide, all-trans retinoic acid, alpha1,25-dihydroxyvitamin D3 or 12-O-tetradecanoyl phorbol-13-acetate. , 1998, Leukemia research.
[117] D. Kraft,et al. Lack of evidence for IgM-induced ADCC: studies with monoclonal and polyclonal antibodies. , 1981, Immunology.
[118] Hyun-Dong Chang,et al. Authentic IgM Fc Receptor (FcμR). , 2017, Current topics in microbiology and immunology.
[119] Maja O’Connor. LONGITUDINAL STUDY , 2013 .
[120] F. Esen,et al. IgM-enriched Immunoglobulins in Sepsis , 2009 .
[121] J. Ravetch,et al. Fcgamma receptors: old friends and new family members. , 2006, Immunity.
[122] J. Ravetch,et al. Fcgamma receptors: old friends and new family members. , 2006, Immunity.
[123] I. Moura,et al. Identification of FcαRI as an Inhibitory Receptor that Controls Inflammation: Dual Role of FcRγ ITAM , 2005 .
[124] J. R. Scotti,et al. Available From , 1973 .
[125] D. C. Henckel,et al. Case report. , 1995, Journal.
[126] I. D. Wilson,et al. The effect of heat inactivation of serum on aggregation of immunoglobulins. , 1979, Immunology.